Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Priced IPO
Solaredge Technologies, Inc. (SEDG)
The Marygold Companies (MGLD)
Blue Water Vaccines (BWV)
Meihua International Medical Technologies (MHUA)
Smart for Life (SMFL)
Vivakor (VIVK)
TC BioPharm Holdings (TCBP)
Direct Digital Holdings, Llc (DRCT)
Modiv (MDV)
Sky Technologies (SKYX)
Modular Medical (MODD)
HeartCore Enterprises (HTCR)
Arcellx, Inc. (ACLX)
Silver Spike Investment Corp. (SSIC)
Maris-Tech Ltd. (MTEK)
Yoshitsu Co., Ltd. (TKLF)
Tpg Inc. (TPG)
Hillstream BioPharma (HILS)
Hour Loop (HOUR)
Vigil Neuroscience, Inc. (VIGL)
More companies

Bionomics Limited (BNOX)

Sector - Healthcare

Price chart

N/A
Return from IPO

Company News

IPO Profile

About company

They are a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need. Ion channels serve as important mediators of physiological function in the CNS and the modulation of ion channels influences neurotransmission that leads to downstream signaling in the brain. The a7 nicotinic acetylcholine (“ACh”) receptor (“a7 receptor”) is an ion channel that plays an important role in driving emotional responses and cognitive performance. Utilizing their expertise in ion channel biology and translational medicine, they are developing orally active small molecule negative allosteric modulators (“NAMs”) and positive allosteric modulators (“PAMs”) of the a7 receptor to treat anxiety and stressor-related disorders and cognitive dysfunction, respectively. They are advancing their lead product candidate, BNC210, an oral proprietary selective NAM of the a7 receptor, for the acute treatment of Social Anxiety Disorder (“SAD”) and chronic treatment of Post-Traumatic Stress Disorder (“PTSD”). They expect to initiate their Phase 2 PREVAIL trial for BNC210 for the acute treatment of SAD by the end of 2021 and currently anticipate reporting topline data by the end of 2022.
Industry
Pharmaceutical Preparations
CEO CFO
-
Employees Founded
7 1996

Contacts

Address: 200 Greenhill Road Eastwood Sa 5063 Australia

Telephone: +618 8150 7400

Web page: http://www.bionomics.com.au

IPO information

First Trade Date 12/16/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 1.6
Shares Revised (MM) 1.62
Expected offer amount (MM) $25.03
Realized offer amount(MM) $20.01

Financial Data (last reporting year)

Market Cap (MM) $106.52
Revenues (MM) $0
Net Income (Loss) (MM) $-7.42

Voting

What do you think will happen with the BNOX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Evercore ISI

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Evercore ISI/ William Blair/ Cantor
CO-Managers
Berenberg/ HC Wainwright

Sector: Healthcare

Tweets about $BNOX

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats